Product Details
STELARA, 5MG/ML, (130 MG), SINGLEDOSE PRESRV FREE VIAL, 1X26 ML
Manufacturer: Centocor
MFG#: 57894-0054-27
NDC: 57894-0054-27
PID: 639855
Additional Information
| Product Name | Stelara, 5 mg/mL, (130 mg), Single-Dose Preservative-Free Vial, 1X26 mL |
| Active Ingredient | Ustekinumab |
| Mechanism of Action | Inhibits IL-12 and IL-23 to reduce inflammatory immune response |
| Strength | 130 mg per 26 mL (5 mg/mL) |
| Route of Administration | Intravenous (IV) for induction, Subcutaneous (SC) for maintenance |
| Dosing Frequency | IV induction followed by SC maintenance dosing every 8-12 weeks |
| Common Side Effects | Nasopharyngitis, headaches, upper respiratory infections, fatigue, injection site reactions |
| Serious Risks | Increased infection risk, tuberculosis reactivation, malignancy |
| Precautions | Screen for tuberculosis before initiation, avoid live vaccines |
| Monitoring Parameters | Signs of infection, tuberculosis screening, immune response |
| Storage Conditions | Store at 2°C to 8°C (36°F to 46°F), do not freeze or shake |
| Packaging | Single-dose vial containing 130 mg ustekinumab in 26 mL |
| Usage | Used to reduce inflammation in autoimmune conditions |
Description
Stelara (ustekinumab) 5 mg/mL is a human monoclonal antibody targeting interleukin-12 (IL-12) and interleukin-23 (IL-23), cytokines involved in immune and inflammatory processes. It is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis in adults. By binding to IL-12 and IL-23, Stelara disrupts cytokine-mediated signaling, reducing inflammation and immune response.
The dosage and administration vary based on the condition being treated. In psoriasis and psoriatic arthritis, Stelara is administered as a subcutaneous injection at weeks 0 and 4, followed by maintenance dosing every 12 weeks. For Crohn’s disease and ulcerative colitis, an initial intravenous infusion is given, followed by subcutaneous maintenance dosing every eight weeks.
Adverse effects include nasopharyngitis, upper respiratory tract infections, headaches, and fatigue. Serious risks involve increased susceptibility to infections, tuberculosis reactivation, and malignancy. Regular monitoring for infections and tuberculosis screening is required before initiation. Patients should not receive live vaccines while on therapy due to immune suppression.
Frequently Asked Questions (FAQs)
The cost of STELARA, 5MG/ML, (130 MG), SINGLEDOSE PRESRV FREE VIAL, 1X26 ML is $available for registerd members only
STELARA, 5MG/ML, (130 MG), SINGLEDOSE PRESRV FREE VIAL, 1X26 ML is manufactured by Centocor.
You can purchase STELARA, 5MG/ML, (130 MG), SINGLEDOSE PRESRV FREE VIAL, 1X26 ML on our website at https://supplies.pipelinemedical.com/product/detail/stelara-5mg-ml-130-mg-singledose-presrv-free-vial-1x26-ml-639855